Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ATAI
SELLAtaiBeckley Inc. · Healthcare · United States · $2.7B · Avg Vol: $121M/d
COMPANY DESCRIPTION
Atai Life Sciences N.V. (ATAI) is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for mental health disorders, including depression, anxiety, and substance use. The company employs a decentralized platform model to identify, invest in, and advance a diverse pipeline of psychedelic and non-psychedelic compounds. This strategic approach aims to accelerate the development of innovative treatments for unmet medical needs in psychiatry.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.2M | 0.3M | 0.3M | 4.1M | 159.9% | 3.5M | 1.1M | 0.2M | -76.9% |
| EPS | -0.44 | -0.11 | -0.42 | -2.91 | — | -2.83 | — | — | — |
| Shares | 368.2M | 368.2M | 368.2M | 363.3M | -1.3% | 370.0M | — | — | — |
| Debt | 15.3M | 19.1M | 24.7M | 2.1M | -48.7% | 5.1M | — | — | — |
| Equity | 260.7M | 243.0M | 116.3M | 221.9M | -5.2% | — | — | — | — |
| Op CF | -104.5M | -84.1M | -82.4M | -102.7M | — | -105.9M | — | — | — |
| Inv CF | -86.8M | -53.3M | 59.2M | -109.1M | — | — | — | — | — |
| Fin CF | 20.8M | -8.4M | 5.4M | 269.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ATAI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ATAI | AtaiBeckley Inc.(you) | $2.7B | 31 | SELL |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | 29 | SELL |
| TARS | Tarsus Pharmaceuticals, Inc. | $2.6B | 27 | SELL |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.6B | 26 | SELL |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.4B | 30 | SELL |
| KOD | Kodiak Sciences Inc. | $2.6B | 26 | SELL |
| TRVI | Trevi Therapeutics, Inc. | $2.5B | 35 | HOLD |
| AGIO | Agios Pharmaceuticals, Inc. | $2.2B | 33 | SELL |
| RAPP | Rapport Therapeutics, Inc. | $1.9B | 32 | SELL |
| SION | Sionna Therapeutics, Inc. | $2.1B | 28 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%